Boston Scientific has announced CE mark approval and European market launch of its Ingenio and Advantio pacemakers and Invive cardiac resynchronisation therapy pacemakers (CRT-P). Marc Burban performed one of the first implants of the Ingenio on the first week of April at the Nouvelles Cliniques Nantaises in Nantes, France.
“The Ingenio device enables physicians to treat pacemaker patients with an advanced and comprehensive set of therapies,” said Burban. “The new RightRate pacing is easy to optimise and is designed to provide needed heart rates for patients to help them feel less fatigued during physical activity.”
“The Ingenio family of pacemakers represents a significant investment in long-term innovation for pacing technologies and defines a new era of pacing for our company,” said Joe Fitzgerald, senior vice president and president of the Boston Scientific Cardiac Rhythm Management group. “In addition, we expect to launch a series of devices with expanded capabilities, that would include remote monitoring, advanced heart failure diagnostics and compatibility with magnetic resonance imaging systems – all designed to provide innovative new features for patient health and well-being.”
The Ingenio and Advantio pacemakers feature RightRate pacing technology designed to treat chronotropic incompetence. RightRate employs Boston Scientific’s minute ventilation sensor, the only sensor clinically proven to restore chronotropic competence, and adds programming options to promote ease of use and in-clinic time savings.
The Ingenio and Advantio pacemakers are currently under review by the US Food and Drug Administration (FDA), and are currently not available for sale in the United States.